Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Alirocumab for treating primary hypercholesterolemia and mixed dyslipidaemia [ID779]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Companies • Regeneron • Sanofi Patient/carer groups • Afiya Trust • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • Cardiovascular Care Partnership • Coronary Prevention Group • Equalities National Council • HEART UK • Muslim Council of Great Britain • Muslim Health Network • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups • British Association for Nursing in Cardiovascular Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Inherited Metabolic Disease Group • British Nuclear Cardiology Society • British Society of Cardiovascular Imaging • British Society for Genetic Medicine	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Possible comparator companies • Accord Healthcare (fluvastatin, pravastatin, simvastatin) • Actavis (atorvastatin, fluvastatin, pravastatin, simvastatin) • Arrow Generics (atorvastatin, pravastatin, simvastatin) • Aspire Pharma (atorvastatin, fluvastatin) • AstraZeneca (rosuvastatin) • Aurobindo Pharma (simvastatin) • Bristol Laboratories (simvastatin) • Bristol-Myers Squibb (pravastatin) • Chanelle Medical (simvastatin) • Dexcel-Pharma (atorvastatin,

Consultees	**Commentators (no right to submit or appeal)**
• Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Health Forum • Vascular Society of Great Britain & Ireland <u>Others</u> • Department of Health • NHS Birmingham South and Central CCG • NHS East Leicestershire and Rutland CCG • NHS England • Welsh Government	simvastatin) • Discovery Pharmaceuticals (simvastatin) • Dr Reddy's Laboratories (atorvastatin) • Kent (pravastatin) • McNeil Products (simvastatin) • Medreich (pravastatin, simvastatin) • Merck, Sharp & Dohme (ezetimibe, simvastatin, simvastatin with ezetimibe) • Mylan (fluvastatin, pravastatin, simvastatin) • Novartis Pharmaceuticals (fluvastatin) • Pfizer (atorvastatin) • Ranbaxy (atorvastatin, pravastatin, simvastatin) • Rosemont Pharma (simvastatin) • Sandoz (fluvastatin, pravastatin, simvastatin) • Sanofi (simvastatin) • Somex (simvastatin) • Teva UK (atorvastatin, fluvastatin pravastatin, simvastatin) • Wockhardt (atorvastatin, simvastatin) • Zentiva (atorvastatin, fluvastatin, pravastatin, simvastatin) <u>Relevant research groups</u> • British Society for Cardiovascular Research • Central Cardiac Audit Database • Cochrane Heart Group • CORDA • MRC Clinical Trials Unit • National Heart Research Fund • National Institute for Health Research • Wellcome Trust - Cardiovascular Research Initiative <u>Evidence Review Group</u> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme

Appendix C

Consultees	**Commentators (no right to submit or appeal)**
	Associated Guideline Groups • National Clinical Guidelines Centre Associated Public Health Groups • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.